Page 70 - Read Online
P. 70

Page 14 of 16      Karolak et al. J Cancer Metastasis Treat 2021;7:15  https://dx.doi.org/10.20517/2394-4722.2021.05

               Conflicts of interest
               All authors declare that there are no conflicts of interest.


               Ethical approval and consent to participate
               Not applicable.


               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2021.


               REFERENCES
               1.       Marchesi I, Fiorentino FP, Rizzolio F, Giordano A, Bagella L. The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma
                   formation. Cell Cycle  2012;11:3828-36.  DOI  PubMed  PMC
               2.       Vella S, Pomella S, Leoncini PP, et al. MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in
                   embryonal rhabdomyosarcoma. Clin Epigenetics  2015;7:82.  DOI  PubMed  PMC
               3.       Shen JK, Cote GM, Gao Y, et al. Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial
                   Sarcoma in vitro. Sci Rep  2016;6:25239.  DOI  PubMed  PMC
               4.       Kawano S, Grassian AR, Tsuda M, et al. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models
                   of Synovial Sarcoma. PLoS ONE  2016;11:e0158888.  DOI  PubMed  PMC
               5.       Zhang P, Garnett J, Creighton CJ, et al. EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell
                   survival and tumourigenesis. J Pathol  2014;232:308-18.  DOI  PubMed  PMC
               6.       Knutson SK, Warholic NM, Wigle TJ, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition
                   of methyltransferase EZH2. Proc Natl Acad Sci U S A  2013;110:7922-7.  DOI  PubMed  PMC
               7.       Moreno N, Kerl K. Preclinical evaluation of combined targeted approaches in malignant rhabdoid tumors. Anticancer Res
                   2016;36:3883-7.  PubMed
               8.       Sun X, Guo W, Shen JK, Mankin HJ, Hornicek FJ, Duan Z. Rhabdomyosarcoma: Advances in Molecular and Cellular Biology.
                   Sarcoma  2015;2015:232010.  DOI  PubMed  PMC
               9.       Shi Y, Wang XX, Zhuang YW, Jiang Y, Melcher K, Xu HE. Structure of the PRC2 complex and application to drug discovery. Acta
                   Pharmacol Sin  2017;38:963-76.  DOI  PubMed  PMC
               10.      Ciarapica R, Miele L, Giordano A, Locatelli F, Rota R. Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first
                   implications. BMC Med  2011;9:63.  DOI  PubMed  PMC
               11.      Ezhkova E, Pasolli HA, Parker JS, et al. Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells.
                   Cell  2009;136:1122-35.  DOI  PubMed  PMC
               12.      Pereira JD, Sansom SN, Smith J, Dobenecker MW, Tarakhovsky A, Livesey FJ. Ezh2, the histone methyltransferase of PRC2,
                   regulates the balance between self-renewal and differentiation in the cerebral cortex. Proc Natl Acad Sci U S A  2010;107:15957-62.
                   DOI  PubMed  PMC
               13.      Zhang Q, Han Q, Zi J, et al. Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasms. Genes Dis
                   2019;6:276-81.  DOI  PubMed  PMC
               14.      Morschhauser F, Tilly H, Chaidos A, et al. Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or
                   Refractory Follicular Lymphoma. Blood  2019;134:123.  DOI
               15.      Je EM, An CH, Yoo NJ, Lee SH. Mutational analysis of PIK3CA, JAK2, BRAF, FOXL2, IDH1, AKT1 and EZH2 oncogenes in
                   sarcomas. APMIS  2012;120:635-9.  DOI  PubMed
               16.      Deng P, Chen QM, Hong C, Wang CY. Histone methyltransferases and demethylases: regulators in balancing osteogenic and
                   adipogenic differentiation of mesenchymal stem cells. Int J Oral Sci  2015;7:197-204.  DOI  PubMed  PMC
               17.      Dudakovic A, Camilleri ET, Xu F, et al. Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2. J Biol
                   Chem  2015;290:27604-17.  DOI  PubMed  PMC
               18.      Hemming S, Cakouros D, Isenmann S, et al. EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage
                   specification. Stem Cells  2014;32:802-15.  DOI  PubMed
               19.      Yu Y, Deng P, Yu B, et al. Inhibition of EZH2 Promotes Human Embryonic Stem Cell Differentiation into Mesoderm by Reducing
                   H3K27me3. Stem Cell Reports  2017;9:752-61.  DOI  PubMed  PMC
               20.      Zhang N, Zeng Z, Li S, Wang F, Huang P. High expression of EZH2 as a marker for the differential diagnosis of malignant and benign
                   myogenic tumors. Sci Rep  2018;8:12331.  DOI  PubMed  PMC
               21.      Wilson BG, Wang X, Shen X, et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic
                   transformation. Cancer Cell  2010;18:316-28.  DOI  PubMed  PMC
               22.      Kadoch C, Copeland RA, Keilhack H. PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease. Biochemistry
                   2016;55:1600-14.  DOI  PubMed
   65   66   67   68   69   70   71   72   73   74   75